CRISPR and Cas Gene Market Analysis

Off-target effects refer to unintended changes or mutations in the genome that occur when the CRISPR-Cas system mistakenly targets and edits DNA sequences other than the intended target. These unintended alterations may lead to potential safety concerns and unpredictability in gene editing outcomes, impacting the efficacy and reliability of CRISPR-based applications. Furthermore, the high cost associated with CRISPR technology may hamper its adoption, particularly in smaller research institutions and organizations with limited budgets.

By product & services, the CRISPR and Cas gene market is classified into product and services. The product segment accounted for 78.7% of the market share in 2022. The expanding range of applications for CRISPR technology, such as genome engineering, disease model studies, and functional genomics will accelerate the industry progression. Also, the increasing government and private spending for enhancement of innovative therapies along with growing adoption of strategic initiatives by industry players.

Based on application, the CRISPR and Cas gene market is segmented into cell line engineering, gRNA design, microbial gene editing, DNA synthesis, and screening. The genome engineering segment accounted for 38.5% of the market share in 2022 due to increasing genomics research and development activities demonstrating the effectiveness of CRISPR technologies. For instance, in May 2021, Vertex and CRISPR Therapeutics presented new clinical data on investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for severe hemoglobinopathies at the annual European Hematology Association Virtual Congress. CTX001 underwent evaluation in two active clinical trials, with the aim of potentially providing a one-time curative treatment for patients affected by transfusion-dependent thalassemia (TDT) and severe sickle cell disease (SCD).

Based on end-use, the CRISPR and Cas gene market is segmented into biotechnology & pharmaceutical companies, academics & government research institutes, and contract research organizations (CROs). The biotechnology & pharmaceutical companies segment is projected to witness lucrative growth of 21.2% by 2032. The growing number of partnerships and collaborations between academic researchers and industry players is expected to foster the adoption of CRISPR technology in the development of cutting-edge treatments and innovative solutions. Also, growing investment by biotechnology companies as well as employing gene modification for both research and commercial applications.

North America CRISPR and Cas gene market accounted for 42.3% market share in 2022. The region's strong biotechnology and pharmaceutical sector encourages research and development in CRISPR technology for drug discovery and therapeutics. Also, increasing government funding and research grants along with well-established healthcare infrastructure & favorable regulatory environment facilitate the adoption of CRISPR in clinical trials and therapeutic applications in the region.